RWA
EVFM

Ropes Wealth Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Ropes Wealth Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2
Closed – – 860
2020
Q4 		$0 Hold
2
– – ﹤0.01% 945
2020
Q3 		$0 Hold
2
– – ﹤0.01% 673
2020
Q2 		$0 Buy
+2
New +$135 ﹤0.01% 621

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
GLA
Great Lakes Advisors Chicago, Illinois $12.1B AUM 29.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ropes Wealth Advisors's EVFM Position: Q1 2021 in Review

Ropes Wealth Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q1 2021, closing a stake of 2 shares.

Ropes Wealth Advisors first reported a position in EVFM in Q2 2020 and held it in 3 quarters. The position peaked at $0 in Q4 2020. 103 funds tracked by Wall St. Rank hold EVFM as of Q1 2021.

  • Ropes Wealth Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Ropes Wealth Advisors sold 2 Evofem Biosciences, Inc. Common Stock shares in Q1 2021.
  • Ropes Wealth Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • Ropes Wealth Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $0 in Q4 2020.
  • 103 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q1 2021.

Based on Ropes Wealth Advisors's 13F filing for Q1 2021, filed 12 May 2021.